Britta Tarp Selected Research

Liver Cirrhosis (Hepatic Cirrhosis)

1/2021	Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
1/2020	Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
8/2018	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Britta Tarp Research Topics

Disease

4	Chronic Hepatitis C 01/2021 - 01/2014
4	Fibrosis (Cirrhosis) 01/2021 - 01/2017
3	Pneumonia (Pneumonitis) 01/2023 - 02/2021
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 08/2018
3	Infections 01/2020 - 01/2014
2	Liver Diseases (Liver Disease) 01/2021 - 01/2020
2	Inflammation (Inflammations) 01/2020 - 08/2018
2	Schistosomiasis (Bilharziasis) 08/2017 - 01/2009
1	Breakthrough Infections 12/2022
1	COVID-19 12/2022
1	Peliosis Hepatis 09/2013

Drug/Important Bio-Agent (IBA)

5	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2014
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 02/2021
3	InterferonsIBA 08/2018 - 01/2014
2	SofosbuvirIBA 01/2020 - 08/2018
2	AntibodiesIBA 08/2017 - 01/2009
2	Ribavirin (Virazole)FDA LinkGeneric 02/2015 - 01/2014
1	COVID-19 VaccinesIBA 12/2022
1	Immunoglobulin G (IgG)IBA 12/2022
1	CollagenIBA 01/2021
1	Complement C4 (Complement Component 4)IBA 01/2021
1	Complement C3 (C3 Complement)IBA 01/2021
1	Galactose (Galactopyranose)FDA LinkGeneric 01/2020
1	Biomarkers (Surrogate Marker)IBA 08/2018
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 08/2018
1	Immunoglobulin E (IgE)IBA 08/2017
1	Antimalarials (Antimalarial Agents)IBA 08/2017
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2014
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 01/2014
1	telaprevirIBA 01/2014
1	Peptide Hydrolases (Proteases)FDA Link 01/2014
1	Oral ContraceptivesIBA 09/2013

Therapy/Procedure

5	Therapeutics 01/2023 - 01/2014
1	Aftercare (After-Treatment) 01/2020
1	Drug Therapy (Chemotherapy) 08/2017